(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

CONFOGEN

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

CONFOGEN

ST13

US500000079404957

Class

1, 5, 35, 42

Filing

79404957

Registration

7877158

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

31

Latest update

07/28/2026

Trademark type

Word

Nice classes

1, 5, 35, 42

Filing date

07/09/2024

Registration date

08/05/2025

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

08/05/2025

Last transaction

07/28/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

32

Owner location

B-9052 Zwijnaarde, BE

Examiner

SWEENEY, MOLLY B

Law office

N30

Current location

FILE REPOSITORY (FRANCONIA)

Holders and representatives

Holders

Confo Therapeutics NV
Confo Therapeutics N.V.

Representatives

Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.

Technical classification

Nice Classes

Class 1Class 5Class 35Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 1

Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substancesantibodies for stabilization of proteinsall the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); proteins for use in science; chimeric proteins to measuretest and develop compounds and ligands binding to G protein-coupled receptors (GPCRs).

Class 5

Pharmaceutical and veterinary preparations for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases; chemical and biochemical substances for pharmaceutical or veterinary use screened by means of stabilized proteinssmall molecules and antibodies for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases; veterinary productsantigens and reagents for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases

Class 35

Collating of data in computer databases; computerized file management; data processing; automated processing of medical and pharmaceutical data; compilation of statistical data relating to medical research and development; computer database management.

Class 42

Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with g protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines.

Publications

History of USPTO decisions and trademark events.

31 publications found

IROP

IRREGULARITY ON NOTICE OF POSSIBLE OPPOSITION RECEIVED FROM IB

07/28/2026

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

07/13/2026

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

07/12/2026

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

03/05/2026

FICS

FINAL DISPOSITION NOTICE SENT TO IB

02/15/2026

FIMP

FINAL DISPOSITION PROCESSED

02/15/2026

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

11/05/2025

CORR

CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED

08/12/2025

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

08/05/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

08/05/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

06/17/2025

PUBO

PUBLISHED FOR OPPOSITION

06/17/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

06/11/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

05/14/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/12/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/12/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

05/12/2025

RFNT

REFUSAL PROCESSED BY IB

04/05/2025

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

03/16/2025

RFRR

REFUSAL PROCESSED BY MPU

03/15/2025

CRCV

CORRECTION TRANSACTION RECEIVED FROM IB

02/14/2025

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

02/07/2025

CNRT

NON-FINAL ACTION WRITTEN

02/06/2025

RFWR

NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW

02/06/2025

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

01/31/2025

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

01/01/2025

CNRT

NON-FINAL ACTION WRITTEN

12/31/2024

DOCK

ASSIGNED TO EXAMINER

12/30/2024

MAFR

APPLICATION FILING RECEIPT MAILED

09/27/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

09/27/2024

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

09/26/2024

Continuous trademark protection

Get notified about every new filing that threatens CONFOGEN or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.